General Information
Mouse: FVB/N x 129S6/SvEvTac
Expression of the mutant (A30P) human alpha-synuclein protein using the P1 artificial chromosome (PAC).
Endogenous alpha synuclein: No
Corresponding human genotype: Autosomal dominant mutation in PD patients (PARK1/PARK4)
Transgene insertion: 4 chromosomal insertions including one in the X chromosome.
References: Kuo 2010
Transgene expression
- 6 weeks-6 months: high but stable expression of the transgene is observed in the whole brain and distal colon.
Neurodegeneration
- 11 and 18 months: no apparent loss of TH-positive neurons is observed in the SN.
Dopamine Homeostasis
- 6 and 12 months: No deficits are observed.
Inclusions
- 6-18 months: no alpha-synuclein abnormalities are observed in the brain. Inclusions are detected in the enteric nervous system.
Motor Behaviours
- No gross motor symptoms (ataxia, tremor, paralysis) are observed at any time
- 6-18 months: no impairments are detected in the rotarod and open field tests.
Response to L-DOPA treatment
- Not reported
Non motor Behaviours
- Colonic deficits: A reduction in expulsion time is observed at 6-12 months (detected only in male and not in female mice). A reduction of the amount of stool that increases with age is observed (greater at 12 months compared to 6 months).
- Whole-gut transit time: increase of transit time (3-12 months).
- Olfaction: no deficits are observed.
- Autonomic dysfunctions: no deficits are observed.
Electrophysiology
- Not reported
Neuroinflammation
- Not reported.